Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

Rhea-AI Summary

Regulus Therapeutics (Nasdaq: RGLS) announced the promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer, effective May 16, 2024. Previously, Dr. Garg was the Senior Vice President of Clinical Development and Regulatory. She has been with Regulus since 2022 and has played a key role in advancing RGLS8429, a treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Dr. Garg has over 20 years of experience in the biopharma industry, holding senior roles at Sanifit Therapeutics, Infinity Pharmaceuticals, Amgen, and Eli Lilly. She holds a B.A. in Biology, an M.D. from the Medical College of Ohio, and an M.S. in Epidemiology from the University of Maryland School of Medicine.

Positive

• Promotion of a highly experienced executive, Rekha Garg, to Chief Medical Officer.
• Dr. Garg's leadership in advancing RGLS8429 for ADPKD, a disease with significant unmet need.
• Dr. Garg's extensive experience in clinical development and regulatory affairs could strengthen Regulus' strategic direction.
• Dr. Garg's background includes senior roles at notable companies like Sanifit Therapeutics, Infinity Pharmaceuticals, Amgen, and Eli Lilly.

Negative

• No mention of immediate financial benefits or stock performance improvements from this appointment.
• Potential risks if the advancement of RGLS8429 does not meet clinical or regulatory milestones.

SAN DIEGO, May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer effective May 16, 2024. Dr. Garg previously served as the Company's Senior Vice President, Clinical Development and Regulatory.

"Dr. Garg has been leading the development and regulatory teams since joining Regulus in 2022," said Jay Hagan, Chief Executive Officer of Regulus Therapeutics. "Her dedication to the Company and the advancement of RGLS8429 has been outstanding and she will continue to play a key role in this new position as our program progresses."

"It's an honor to become Chief Medical Officer and I'm excited to have this unique opportunity to make a meaningful impact on patients with ADPKD, a disease with significant unmet need," said Rekha Garg, Chief Medical Officer. "I look forward to advancing our program through the next stages of clinical development in partnership with the rest of the leadership team."

Dr. Garg is a physician executive with over 20 years of experience in leadership roles in the biopharma industry, across multiple therapeutic areas including kidney disease. Before joining Regulus, she was Senior Vice President, Regulatory Affairs and Safety, at Sanifit Therapeutics. Prior to that, she was Vice President at Infinity Pharmaceuticals and served in multiple leadership roles in clinical development, regulatory affairs, and risk management at Amgen and Eli Lilly. Prior to joining the pharmaceutical industry, she held a similar role at the National Heart, Lung, and Blood Institute. Dr. Garg received her B.A. in Biology from Oberlin College, her M.D. from the Medical College of Ohio and completed her residency at the University of Maryland School of Medicine where she also received an M.S. in Epidemiology.

About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Forward-Looking Statements
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, the expected timing for initiating clinical studies, potentially achieving therapeutic efficacy and clinical translation for ADPKD patients, the expected timing for reporting topline data, the timing and future occurrence of other preclinical and clinical activities and the expected length of our cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the approach we are taking to discover and develop drugs is novel and may never lead to marketable products, preliminary or initial results may not be indicative of future results, preclinical and clinical studies may not be successful, risks related to regulatory review and approval, risks related to our reliance on third-party collaborators and other third parties, risks related to intellectual property, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative and our need for additional capital. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus' most recently filed quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-promotion-of-rekha-garg-md-ms-to-chief-medical-officer-302147030.html

SOURCE Regulus Therapeutics Inc.

FAQ

Who is the new Chief Medical Officer of Regulus Therapeutics?

Rekha Garg, M.D., M.S., was promoted to Chief Medical Officer effective May 16, 2024.

What role did Rekha Garg have before becoming Chief Medical Officer at Regulus Therapeutics?

Dr. Garg was previously the Senior Vice President of Clinical Development and Regulatory at Regulus Therapeutics.

When did Rekha Garg join Regulus Therapeutics?

Dr. Garg joined Regulus Therapeutics in 2022.

What is RGLS8429 and what disease is it targeting?

RGLS8429 is a treatment being developed for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

What are Dr. Rekha Garg's qualifications?

Dr. Garg holds a B.A. in Biology, an M.D. from the Medical College of Ohio, and an M.S. in Epidemiology from the University of Maryland School of Medicine.